Gourt > Health > Pharmacy > Drugs and Medications > T > Tipranavir
Tipranavir, or tipranavir disodium, is a nonpeptidic protease inhibitor (PI) with the trade name Aptivus®. It is used in combination therapy to treat HIV infection.
Tipranavir has the ability to inhibit the replication of viruses that are resistant to other protease inhibitors. Resistance to tipranavir itself seems to require multiple mutations. Tipranavir is given in combination with Ritonavir 200 mg twice daily.
Tipranavir was approved by the Food and Drug Administration (FDA) on June 22, 2005. Nelfinavir is the only other FDA approved nonpeptidic protease inhibitor. Like lopinavir and atazanavir, it is very potent and is effective in salvage therapy for patients with some drug resistance. However, it tends to have more side effects.
More on [ Tipranavir ]
Tipranavir - Mechanism of Action. http://t.co/wriE2ieu
SympoPharmaco (Symposier Pharmaco) Sun, 18 Dec 2011 05:10:28 -0000
Tipranavir - Mechanism of Action. http://t.co/wriE2ieu
Aptivus - Information from RxList
Meta Description: [ Description Monographs include chemistry, chemical structure, inactive ingredients ]
Tipranavir: Patient Information Sheet - Information for patients from the US Food and Drug Administration (FDA).
Meta Description: [ Tipranavir (marketed as Aptivus): Patient Information Sheet ]
| New Therapy for HIV Patients with Advanced Disease (Oct '05) | |
